Complementing these clinical observations, Zhao et al. (2023) elucidated the mechanistic role of the RvD2/GPR18 axis in cardiovascular and metabolic diseases, demonstrating a reduction in cerebral infarct size, attenuation of edema, and modulation of vascular inflammation. The gene discussed is GPR18; the disease is metabolic disease.